
Nuvation Bio (NUVB) Stock Forecast & Price Target
Nuvation Bio (NUVB) Analyst Ratings
Bulls say
Nuvation Bio is expected to see significant revenue growth from its product candidate, taletrectinib, which is a highly effective, orally administered treatment for ROS1+ NSCLC. Additionally, the company's pipeline of other oncology product candidates and out-licensing collaborations provides a diverse range of revenue streams. Potential risks include negative clinical data for pipeline programs and slower-than-anticipated commercial uptake, but the company's strong management team and focus on educating the NSCLC community bode well for future success.
Bears say
Nuvation Bio is facing near-term commercialization risks for Ibtrozi and regulatory risks for Safusidenib, which would impact future product revenue. Although the company has a strong financial position with $533.7MM in cash, the market may be underestimating the differentiated potential of Safusidenib in IDH1-mutant glioma and the potential of its DDC platform. Therefore, the negative outlook is due to the uncertainty and risks associated with the company's current and future product revenue.
This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.
Nuvation Bio (NUVB) Analyst Forecast & Price Prediction
Start investing in Nuvation Bio (NUVB)
Order type
Buy in
Order amount
Est. shares
0 shares